<a href="https://laohu8.com/S/PMCB">PharmaCyte Biotech</a> Faces Nasdaq Delisting Risk Over Bid Price Rule Compliance
PharmaCyte Biotech Inc. has received a notice from the Nasdaq Stock Market indicating non-compliance with the minimum bid price requirement of $1.00 per share, as outlined in Nasdaq Listing Rule 5550(a)(2). The company now has 180 calendar days, until June 1, 2026, to regain compliance by maintaining a closing bid price of at least $1.00 per share for a minimum of 10 consecutive business days. If compliance is not achieved within this period, PharmaCyte may be eligible for an additional 180-day extension if other initial listing requirements are met. Failure to regain compliance could result in the company's securities being delisted from the Nasdaq Capital Market. The notice does not affect the company's business operations or its SEC reporting obligations.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. PharmaCyte Biotech Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001683168-25-008947), on December 05, 2025, and is solely responsible for the information contained therein.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。